×
About 13,445 results

ALLMedicine™ Triple-negative Breast Cancer Center

Research & Reviews  6,157 results

Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With...
https://doi.org/10.1001/jama.2021.2786
JAMA Bi XW, Hua X et. al.

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer-Reply.|2021|Bi XW,Hua X,Yuan ZY,|

Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With...
https://doi.org/10.1001/jama.2021.2780
JAMA Du F, Yuan P

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.|2021|Du F,Yuan P,|

Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progress...
https://doi.org/10.18632/aging.202925
Aging Wu JY, Chien YC et. al.

May 2nd, 2021 - Capsanthin is a naturally occurring red pepper carotenoid with possible antitumor activity, but its antitumor mechanisms have yet to be delineated. We tested the anti-proliferative activity of capsanthin with human triple-negative breast cancer (T...

A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of t...
https://doi.org/10.1002/jcla.23779
Journal of Clinical Laboratory Analysis; Wu J, Cai Y et. al.

May 2nd, 2021 - Patients with triple-negative breast cancer (TNBC) face a major challenge of the poor prognosis, and N6-methyladenosine-(m6A) mediated regulation in cancer has been proposed. Therefore, this study aimed to explore the prognostic roles of m6A-relat...

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified ...
https://doi.org/10.1186/s13058-021-01428-5 10.1038/nrc.2016.72 10.1200/JCO.2014.57.1414 10.1056/NEJMra0809889 10.1038/nrc1878 10.1371/journal.pgen.1007752 10.1016/j.jmoldx.2016.10.002 10.1038/nature19057 10.1093/nar/gkg509 10.1093/nar/gkr407 10.1002/humu.21047 10.1038/nm.4292 10.1016/j.ccell.2019.02.001 10.1074/jbc.274.9.5659 10.1038/nature24060
Breast Cancer Research : BCR; Zheng Y, Li B et. al.

May 2nd, 2021 - We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast cancer patient who la...

see more →

Guidelines  37 results

Expanding the role of PARP inhibitors in breast cancer
https://www.mdedge.com/hematology-oncology/article/223054/breast-cancer/expanding-role-parp-inhibitors-breast-cancer

May 30th, 2020 - For patients with BRCA-like triple-negative breast cancer (TNBC), adding veliparib to cisplatin chemotherapy may extend survival, based on results from the phase 3 SWOG S1416 trial.

Metronomic capecitabine maintenance extends DFS in triple-negative breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{3c339a48-87d5-48c1-ad53-432291e3e553}/metronomic-capecitabine-maintenance-extends-dfs-in-triple-negative-breast-cancer

May 29th, 2020 - A year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer, according to study results presented at ASCO20 Virtual Scientific Program.

PPI added to chemo improves breast tumor response rate
https://www.mdedge.com/hematology-oncology/article/223037/breast-cancer/ppi-added-chemo-improves-breast-tumor-response-rate

May 29th, 2020 - The proton pump inhibitor (PPI) omeprazole may be a useful addition to treatment for triple-negative breast cancer, as it boosted the expected rate of tumor disappearance among women with early-stage disease, according to the results of a phase 2 ...

Capecitabine maintenance improved DFS, not OS, in TNBC patients
https://www.mdedge.com/hematology-oncology/article/223038/breast-cancer/capecitabine-maintenance-improved-dfs-not-os-tnbc

May 29th, 2020 - For patients with triple-negative breast cancer (TNBC), 1 year of capecitabine treatment after standard therapy may lead to significantly better disease-free survival (DFS), but not overall survival (OS), according to results of a phase 3 trial.

see more →

Drugs  1 results see all →

Clinicaltrials.gov  6,815 results

Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With...
https://doi.org/10.1001/jama.2021.2786
JAMA Bi XW, Hua X et. al.

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer-Reply.|2021|Bi XW,Hua X,Yuan ZY,|

Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With...
https://doi.org/10.1001/jama.2021.2780
JAMA Du F, Yuan P

May 4th, 2021 - Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.|2021|Du F,Yuan P,|

Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progress...
https://doi.org/10.18632/aging.202925
Aging Wu JY, Chien YC et. al.

May 2nd, 2021 - Capsanthin is a naturally occurring red pepper carotenoid with possible antitumor activity, but its antitumor mechanisms have yet to be delineated. We tested the anti-proliferative activity of capsanthin with human triple-negative breast cancer (T...

A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of t...
https://doi.org/10.1002/jcla.23779
Journal of Clinical Laboratory Analysis; Wu J, Cai Y et. al.

May 2nd, 2021 - Patients with triple-negative breast cancer (TNBC) face a major challenge of the poor prognosis, and N6-methyladenosine-(m6A) mediated regulation in cancer has been proposed. Therefore, this study aimed to explore the prognostic roles of m6A-relat...

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified ...
https://doi.org/10.1186/s13058-021-01428-5 10.1038/nrc.2016.72 10.1200/JCO.2014.57.1414 10.1056/NEJMra0809889 10.1038/nrc1878 10.1371/journal.pgen.1007752 10.1016/j.jmoldx.2016.10.002 10.1038/nature19057 10.1093/nar/gkg509 10.1093/nar/gkr407 10.1002/humu.21047 10.1038/nm.4292 10.1016/j.ccell.2019.02.001 10.1074/jbc.274.9.5659 10.1038/nature24060
Breast Cancer Research : BCR; Zheng Y, Li B et. al.

May 2nd, 2021 - We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast cancer patient who la...

see more →

News  435 results

Biologic Drug Nearly Doubles Overall Survival in Metastatic Triple-Negative Breast Cancer
https://www.medscape.com/viewarticle/949703

Apr 21st, 2021 - NEW YORK (Reuters Health) - Immunomedics' antibody-drug conjugate sacituzumab govitecan can cut the risk of disease progression or death by 59% and nearly double median overall survival among women with metastatic triple-negative breast cancer, ac...

Anthracycline-Free Neoadjuvant Regimen Safe, Effective for TNBC
https://www.medscape.com/viewarticle/946934

Mar 4th, 2021 - For patients with triple-negative breast cancer (TNBC), neoadjuvant carboplatin plus docetaxel yields the same pathologic complete response and survival rates as a standard anthracycline-based neoadjuvant regimen ― carboplatin and paclitaxel follo...

Long-Term Metformin Use Linked to Fewer ER+ Breast Cancers
https://www.medscape.com/viewarticle/945174

Feb 2nd, 2021 - Researchers say women with type 2 diabetes treated with metformin had a reduced rate of the most common type of breast cancer, estrogen receptor (ER)-positive tumors, during a median follow-up of nearly 9 years in a prospective study of more than ...

Sacituzumab Govitecan in Patients With Metastatic TNBC
https://decisionpoint.medscape.com/oncology/viewarticle/917169

Feb 2nd, 2021 - This transcript has been edited for clarity. I'm excited to update you on some of the progress that's been made about sacituzumab govitecan over the past couple of weeks. So, sacituzumab govitecan is an antibody-drug conjugate. The antibody part i...

A Disappointment in Triple-Negative Breast Cancer
https://www.medscape.com/viewarticle/942747

Dec 15th, 2020 - Adding the oral AKT inhibitor ipatasertib to paclitaxel does not improve progression-free survival (PFS) for women with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), suggests the phase ...

see more →